Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Total article views   Abstract views HTML views PDF downloads Totals
13,846 Dovepress* 10,477 1,319+ 1,320 11,796
PubMed Central* 0 2,050 460 2,050
Totals 10,477 3,369 1,780 13,846
*Since 11 November 2016
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
8 0 0 0 3 5

View citations on PubMed Central and Google Scholar